Onco-Innovations Limited (CBOE CA: ONCO)(OTCQB: ONNVF)(Frankfurt: W1H, WKN: A3EKSZ)（&#34; Onco&#34; 或 &#34; 公司&#34;）宣布已聘请 i2i Marketing Group, LLC（地址：1107 Key Plaza, Suite 222, Key West, FL 33040, USA；电子邮件：contact@i2illc.com；电话：（240）315-4665；联系人：Joe Grubb）提供市场宣传和企业沟通服务，包括内容创作、项目管理、第三方媒体分发和数字市场宣传活动。
公司还宣布已从之前与另一家提供商的市场宣传合作中获得剩余未使用余额 €213,000（详见公司于 2025 年 10 月 30 日发布的新闻稿）。
根据与 i2i 的协议，初始市场宣传预算为 400,000 美元。该项目计划持续到 2026 年 7 月 14 日，或预算耗尽，并结构化以便根据市场情况进行持续评估和优化。公司认为，保持一致、合规的市场宣传是支持可见性和长期股东基础发展的重要组成部分。
据公司所知，i2i Marketing Group, LLC 对公司的证券没有任何直接或间接的利益。
关于 Onco-Innovations Limited
Onco-Innovations 是一家总部位于加拿大的公司，致力于癌症研究和治疗，专注于肿瘤学。Onco 的使命是通过开创性的研究和创新解决方案来追求癌症的预防和治疗。该公司已获得针对实体肿瘤的专利技术的全球独家许可。
代表 Onco-Innovations Limited，
&#34; Thomas O'Shaughnessy&#34;
首席执行官
如需更多信息，请联系：
Thomas O'Shaughnessy
首席执行官
电话：+ 1 888 261 8055
investors@oncoinnovations.com
前瞻性声明警告。 本新闻稿包含前瞻性声明，包括与公司业务和计划相关的声明，以及其他非历史事实的声明。前瞻性声明通常通过诸如 “将”、“可能”、“潜在”、“应该”、“预期”、“期望” 等类似表达来识别。除历史事实声明外，本发布中包含的所有声明均为涉及风险和不确定性的前瞻性声明。不能保证这些声明将被证明是准确的，实际结果和未来事件可能与这些声明中预期的有实质性差异。读者应注意，准备任何前瞻性信息时使用的假设可能被证明是错误的。事件或情况可能导致实际结果与预测的有实质性差异，原因是许多已知和未知的风险、不确定性和其他因素，其中许多超出了公司的控制。读者应谨慎对待任何前瞻性信息。尽管管理层在准备时认为这些信息是合理的，但可能被证明是错误的，实际结果可能与预期有实质性差异。本新闻稿中包含的前瞻性声明明确受到此警告声明的限制。本新闻稿中包含的前瞻性声明截至本新闻稿日期，公司将根据适用法律的明确要求，公开更新或修订任何包含的前瞻性声明。
来源： Onco-Innovations Limited
查看原始新闻稿，请访问 ACCESS Newswire
<img src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTEyOTgwNQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTEyOTgwNQ"/>

Onco-Innovations Limited 已与 i2i Marketing Group 签订市场宣传服务合同，初始预算为 400,000 美元。该项目将持续到 2026 年 7 月 14 日，旨在提升企业沟通和可见度。公司还报告了来自之前合作的 213,000 欧元的回报。Onco-Innovations 专注于癌症研究，并拥有针对实体肿瘤的技术的独占权。公告中的前瞻性声明警告称，由于各种风险和不确定性，实际结果可能与预期有所不同

Onco-Innovations Limited (CBOE CA: ONCO)(OTCQB: ONNVF)(Frankfurt: W1H, WKN: A3EKSZ) (&#34; Onco&#34; or the &#34; Company&#34;) announces that it has engaged i2i Marketing Group, LLC (1107 Key Plaza, Suite 222, Key West, FL 33040, USA; email: contact@i2illc.com; telephone: (240) 315-4665; Contact: Joe Grubb) to provide market awareness and corporate communications services, including through content creation, project management, third-party media distribution, and digital market awareness initiatives.
<div class="lb-trans">Onco-Innovations Limited (CBOE CA: ONCO)(OTCQB: ONNVF)(Frankfurt: W1H, WKN: A3EKSZ)（&#34; Onco&#34; 或 &#34; 公司&#34;）宣布已聘请 i2i Marketing Group, LLC（地址：1107 Key Plaza, Suite 222, Key West, FL 33040, USA；电子邮件：contact@i2illc.com；电话：（240）315-4665；联系人：Joe Grubb）提供市场宣传和企业沟通服务，包括内容创作、项目管理、第三方媒体分发和数字市场宣传活动。
</div>The Company also announces that it has obtained a return of the remaining unused balance of €213,000 from its prior market awareness engagement with another provider (see Company press release dated October 30, 2025).
<div class="lb-trans">公司还宣布已从之前与另一家提供商的市场宣传合作中获得剩余未使用余额 €213,000（详见公司于 2025 年 10 月 30 日发布的新闻稿）。
</div>The initial market awareness budget under the agreement with i2i is USD $400,000. The program is scheduled to run until July 14, 2026, or budget exhaustion, and is structured to allow for ongoing evaluation and optimization based on market conditions. The Company believes that maintaining consistent, compliant market awareness is an important component of supporting visibility, and long-term shareholder base development.
<div class="lb-trans">根据与 i2i 的协议，初始市场宣传预算为 400,000 美元。该项目计划持续到 2026 年 7 月 14 日，或预算耗尽，并结构化以便根据市场情况进行持续评估和优化。公司认为，保持一致、合规的市场宣传是支持可见性和长期股东基础发展的重要组成部分。
</div>To the Company's knowledge, i2i Marketing Group, LLC does not have any interest, directly or indirectly, in the securities of the Company.
<div class="lb-trans">据公司所知，i2i Marketing Group, LLC 对公司的证券没有任何直接或间接的利益。
</div>About Onco-Innovations Limited
<div class="lb-trans">关于 Onco-Innovations Limited
</div>Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours.
<div class="lb-trans">Onco-Innovations 是一家总部位于加拿大的公司，致力于癌症研究和治疗，专注于肿瘤学。Onco 的使命是通过开创性的研究和创新解决方案来追求癌症的预防和治疗。该公司已获得针对实体肿瘤的专利技术的全球独家许可。
</div>ON BEHALF OF ONCO-INNOVATIONS LIMITED,
<div class="lb-trans">代表 Onco-Innovations Limited，
</div>&#34; Thomas O'Shaughnessy&#34;
<div class="lb-trans">&#34; Thomas O'Shaughnessy&#34;
</div>Chief Executive Officer
<div class="lb-trans">首席执行官
</div>For more information, please contact:
<div class="lb-trans">如需更多信息，请联系：
</div>Thomas O'Shaughnessy
<div class="lb-trans">Thomas O'Shaughnessy
</div>Chief Executive Officer
<div class="lb-trans">首席执行官
</div>Tel: + 1 888 261 8055
<div class="lb-trans">电话：+ 1 888 261 8055
</div>investors@oncoinnovations.com
<div class="lb-trans">investors@oncoinnovations.com
</div>Forward-Looking Statements Caution. This news release contains forward-looking statements, including in relation to the Company's business and plans generally, and other statements that are not historical facts. Forward-looking statements are often identified by terms such as &#34;will&#34;, &#34;may&#34;, &#34;potential&#34;, &#34;should&#34;, &#34;anticipate&#34;, &#34;expects&#34; and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.
<div class="lb-trans">前瞻性声明警告。 本新闻稿包含前瞻性声明，包括与公司业务和计划相关的声明，以及其他非历史事实的声明。前瞻性声明通常通过诸如 “将”、“可能”、“潜在”、“应该”、“预期”、“期望” 等类似表达来识别。除历史事实声明外，本发布中包含的所有声明均为涉及风险和不确定性的前瞻性声明。不能保证这些声明将被证明是准确的，实际结果和未来事件可能与这些声明中预期的有实质性差异。读者应注意，准备任何前瞻性信息时使用的假设可能被证明是错误的。事件或情况可能导致实际结果与预测的有实质性差异，原因是许多已知和未知的风险、不确定性和其他因素，其中许多超出了公司的控制。读者应谨慎对待任何前瞻性信息。尽管管理层在准备时认为这些信息是合理的，但可能被证明是错误的，实际结果可能与预期有实质性差异。本新闻稿中包含的前瞻性声明明确受到此警告声明的限制。本新闻稿中包含的前瞻性声明截至本新闻稿日期，公司将根据适用法律的明确要求，公开更新或修订任何包含的前瞻性声明。
</div>SOURCE: Onco-Innovations Limited
<div class="lb-trans">来源： Onco-Innovations Limited
</div>View the original press release on ACCESS Newswire
<div class="lb-trans">查看原始新闻稿，请访问 ACCESS Newswire
</div><img src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTEyOTgwNQ" alt="" original-src="https://app.accessnewswire.com/img.ashx?id=1129805"/>

Onco-Innovations Engages i2i Marketing Group Engagement for Market Awareness Services | ONNVF Stock News

StockTitan

标普生物技术 ETF - SPDR

动态生物技术与基因组 ETF - Invesco

Invesco Nasdaq Biotechnology ETF

纳斯达克生物科技指数 ETF - iShares Nasdaq

美国制药 ETF - iShares

标普全球医疗股指数 ETF - iShares

Onconetix

医疗业 ETF - Vanguard

2 倍做多纳斯达克生物技术 ETF - ProShares

Inovio 制药

Oncolytics生物科技

生物科技 ETF - VanEck Vectors

纽交所高增长板生物技术指数 ETF - First Trust

基因改革 ETF - ARK

医药突破 ETF - ALPS

医疗业 ETF - SPDR

Onco-Innovations 与 i2i 营销集团合作以提升市场认知度 | ONNVF 股票新闻